LISCure Biosciences creates a new therapeutic paradigm with
microorganism-based medicines.

COMPANY

 The Great Pioneer for Incurable Diseases The Great Pioneer for Incurable Diseases

LISCure Biosciences is a clinical-stage pharmaceutical company focusing on “injectable bacteria-mediated cancer immunotherapy” and “oral microbiome therapeutics.”

LISCure Biosciences is a clinical-stage pharmaceutical company focusing on “injectable bacteria-mediated cancer immunotherapy” and “oral microbiome therapeutics.”

About Leadership Partners

TECHNOLOGY

 Innovative Platform Technology Based on Microbiology and Genomics Innovative Platform Technology Based on Microbiology and Genomics

The LMT (LISCure Microbiology-based Technology) platform is used to discover and analyze microorganism-based drug candidates. It consists of a therapeutic screening platform, a microbial optimization platform, and a microbiome database platform.

VIEW MORE

PIPELINE

 Addressing Areas of High Unmet Medical Needs Including Oncology, Liver Diseases, Neuroscience, and Immunology Addressing Areas of High Unmet Medical Needs Including Oncology, Liver Diseases, Neuroscience, and Immunology

We are conducting a number of global clinical trials, and we have partnered with reputable research institutes, such as Mayo Clinic and Scripps Research, to jointly research and develop liver disease and immuno-oncology programs.

VIEW MORE

  • Indication
  • Product
  • Collaborators
  • Discovery
  • In-Vivo Efficacy
  • IND Enabling
  • Phase 1
  • Phase 2
  • Microbiome Therapeutics
  • LIVER DISEASES
    LIVER DISEASES
    IMMUNOLOGY
    NEUROSCIENCE
    LIVER DISEASES
  • LB-P8
    LB-P8
    LB-P6
    LB-P4
    LB-P7

    NASH & NAFLD

    2022

    Cholestatic Liver Disease

    2023

    Auto-immune Disease

    2023

    Parkinson’s Disease/Alzheimer’s Disease

    2023

    Combination Studies

  • Bacteria-mediated
    Immunotherapy
  • ONCOLOGY
  • LB-P2D
    LB-P1
    LB-P3
    LB-P10
    LB-P11

    Solid Tumors (metastatic cancers)

    2022

    Solid Tumors

    Solid Tumors

    Solid Tumors

    Solid Tumors

  • Bacterial EV
  • NEUROSCIENCE
    IMMUNOLOGY
  • LB-P4E
    LB-P6E
  1. Research Collaboration
  2. 01. Research Collaboration with Mayo Clinic (LB-P7&P8 NASH)
  3. 02. Research Collaboration with Mayo Clinic (LB-P8 Rare Liver Diseases)
  4. 03. Research Collaboration with The Scripps Research Institute (LB-P2D Immuno-Oncology)

IR/PR

 Check out the Notice
PR Celltrion and LISCure Biosciences announce strategic collaboration to ..

■ Co-research and co-development of novel microbiome therapeutics■Discovery of new candidates to meet high unmet medica..

2023.02.21
PR LISCure's Phase 2 Drug Candidate Granted Orphan Drug Designation (ODD)..

First Orphan Drug Designation (ODD) in the field of microbiome-based treatment for metabolic diseasesSEOUL, South Korea,..

2022.12.09
PR LISCure Biosciences Announces Oral Presentation of New Drug Candidate ..

The efficacy and mechanism of NASH microbiome-based therapy for liver fibrosis, steatosis, and inflammation have been co..

2022.10.28
PR LISCure Biosciences Announces Research Collaboration with The Scripps ..

SEOUL, South Korea,Feb. 3, 2022/PRNewswire/ --LISCure Biosciences ("LISCure") announced that it had reached an..

2022.02.03
PR LISCure Biosciences announces research collaboration with Mayo Clinic ..

SEOUL, South Korea,Jan. 6, 2022/PRNewswire/ -- LISCure Biosciences Inc., a leading biotech focused on microbial-based th..

2022.01.06
PR LISCure Biosciences received clinical approval for two microbiome prog..

SEOUL, South Korea,Sept. 30, 2021/PRNewswire/ -- LISCure Biosciences ("LISCure") announced that it has receive..

2021.10.01
PR LISCure Biosciences Announces Know-How License Agreement and Stock Pur..

SEOUL, South Korea, Aug. 1, 2021 /PRNewswire/ -- LISCure Biosciences, Inc. ("LISCure") has entered into a kno..

2021.08.01
PR LISCure Biosciences Successfully Raises $21 million in Series B Fundin

SEOUL, South Korea,Feb. 26, 2021/PRNewswire/ -- OnFebruary 25th, 2021, LISCure Biosciences Inc., a biotech company that ..

2021.02.26
PR LISCure Biosciences Has Completed Seed Funding of USD 5 Million for Ba..

SEOUL, South Korea,July 25, 2019/PRNewswire/ -- LISCure Biosciences, a biotech company that researches and develops bact..

2019.07.25